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Accelerated stem cell labeling
with ferucarbotran and protamine
Abstract Objective: To develop and
characterize a clinically applicable,
fast and efficient method for stem cell
labeling with ferucarbotran and prot-
amine for depiction with clinical
MRI. Methods: The hydrodynamic
diameter, zeta potential and relaxiv-
ities of ferucarbotran and varying
concentrations of protamine were
measured. Once the optimized ratio
was found, human mesenchymal stem
cells (MSCs) were labeled at varying
incubation times (1–24 h). Viability
was assessed via Trypan blue exclu-
sion testing. 150,000 labeled cells in
Ficoll solution were imaged with T1-,
T2- and T2*-weighted sequences at 3
T, and relaxation rates were calcu-
lated. Results: Varying the concen-
trations of protamine allows for easy
modification of the physicochemical
properties. Simple incubation with
ferucarbotran alone resulted in effi-
cient labeling after 24 h of incubation
while assisted labeling with protamine
resulted in similar results after only
1 h. Cell viability remained unaf-
fected. R2 and R2* relaxation rates
were drastically increased. Electron
microscopy confirmed intracellular
iron oxide uptake in lysosomes. Re-
laxation times correlated with results
from ICP-AES. Conclusion: Our
results show internalization of feru-
carbotran can be accelerated in MSCs
with protamine, an approved heparin
antagonist and potentially clinically
applicable uptake-enhancing agent.
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Introduction
Cell replacement therapy is a promising therapeutic
approach for diseases such as type 1 diabetes mellitus
[1], Parkinson’s disease [2] or myocardial infarction (MI)
[3]. Stem cells play an important role as a source of cells
destined for implantation. Mesenchymal stem cells (MSCs)
are non-hematopoietic stem cells derived from bone
marrow and have the distinct advantages of being well
characterized, easily obtained and efficiently expanded in
vitro compared with other stem cell populations [4].
Patients who received autologous MSCs after an acute MI
showed favorable left ventricular remodeling and better
ejection fractions than patients who received a placebo [5].
Unfortunately, detecting what happens to engrafted cells
after transplantation remains difficult. Magnetic resonance
(MR) imaging can provide a non-invasive, real-time
diagnostic method for tracking implanted cells [6].
In order to detect implanted cells via MR imaging, they
must be labeled with a contrast agent. Most labeling studies
have been conducted using superparamagnetic iron oxide
particles (SPIO) or ultrasmall SPIOs (USPIO), which
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Fax: +1-415-4760616function by creating local field inhomogeneities that cause
decreased signal on T2- and T2*-weighted images [7]. Iron
oxide-based contrast agents show high MR sensitivity and
good biocompatibility [8]. Cell labeling can be achieved by
simple incubation with contrast agents [9–11]. Enhanced
uptake can be achieved by linking SPIOs to HIV Tat
peptides [12] or by using poly-L-lysine (PLL) [10],
lipofectamine [10] or dendrimers [13]. While cellular
uptake using these agents is greatly increased, these agents
are unfortunately not approved by health authorities.
Protamine is a low molecular weight polycationic
peptide that is approved as an antidote for heparin
anticoagulation [14]. It is also used as a transfection
agent for DNA [15] and oligonucleotides [16]. Arbab et al.
have shown that protamine can aid in the uptake of
ferumoxides for the application of cell labeling [17].
Ferucarbotran (Resovist) is a SPIO with a carboxydextran
coating, a net negative charge and a hydrodynamic
diameter slightly smaller than ferumoxides. It is currently
in clinical use in Europe for MR examination of focal
liver lesions and possesses advantages compared with
other iron-based contrast agents, such as its ability to be
administered in a bolus. It has been shown that the
cellular uptake in monocytes of ferucarbotran is greater
and its induction of apoptosis is lower when compared
with ferumoxides [18]. Thus, it seems that the combina-
tion of protamine and ferucarbotran is promising in order
to develop a clinically applicable, fast and efficient
method for stem cell labeling for subsequent depiction
with MRI.
Materials and methods
Contrast agent
Ferucarbotran (Resovist, Bayer Schering Pharma AG, Berlin,
Germany) are SPIO particles that are coated with carbox-
ydextran [19]. It has been approved for the MR characteriza-
tion of focal liver lesions in Europe since 2001. The contrast
agent has an r1 relaxivity of 8.7 (8.2–9.2) mM
−1s
−1,r 2
relaxivity of 61 (54–68) mM
−1s
−1 (at 37°C and 1.5 T in
water) and an overall hydrodynamic diameter of 62 nm
[19, 20]. The carboxydextran coating ensures optimal
dispersion of the nanoparticles within aqueous solutions
and bestows upon the complex a net negative charge.
Contrast agent was provided as a 1.4-ml ready-to-inject
syringe of 0.5 M iron.
Protamine is a group of small (molecular weight 4000–
4250) cationic peptides with a high arginine content [14]. It
occurs naturally in sperm where it assists in forming a
compact structure by binding DNA. Clinically, it is used
as an antidote to heparin–induced anticoagulation and as
a complexing agent where it prolongs the duration of
action of insulin (in the form of NPH insulin). Protamine
sulphate stock solution of 50 mg in 5 ml saline solution
(0.9%) was obtained (American Pharmaceutical Partners
Inc., Schaumberg, IL).
Complex formation between ferucarbotran and protamine
was performed by mixing constant concentrations of
ferucarbotran (iron concentration of 50 μg/ml) and various
concentrations of protamine (0, 1, 3, 5, 7, 10 μg/ml).
Respective substances were added directly to the labeling
media [Dulbecco’s Modified Eagle Medium (DMEM) +
25% fetal calf serum (FCS)], vigorously shaken and left for
10 min, after which the complexes were utilized for further
experiments.
Physicochemical properties
Measurement of size, zeta potential and relaxivity of the
contrast agent protamine complexes was performed. The
hydrodynamic diameter of the complexes was determined
by dynamic light scattering with a Zetasizer 3000 HAS
(Malvern Instruments, Herrenberg, Germany). The mea-
surement was performed in labeling media (DMEM + 25%
FCS) in order to correctly measure the effective hydrody-
namic diameter as would be pertinent to a cell. Five
individual measurements were performed on each sample.
The surface charge of the complexes was determined by
measuring the electrophoretic mobility in a microelectro-
phoresis flow cell using a Zetasizer 3000 HAS. To negate
the effect of charged particles in the labeling solution,
preparation and measurement of the complexes were
performed in distilled water. Zeta potentials were measured
at least ten times on each sample.
A 1.5-T clinical system (Philips Achieva, Philips
Healthcare, Best, The Netherlands) was used for measuring
the relaxivity of ferucarbotran/protamine complexes in
labeling media. Samples with 1.5 ml of the complex were
imaged in Eppendorf tubes placed inside a wrist coil
(Medical Advances Inc, Milwaukee, WI). For the simulta-
neous measurement of T1 and T2, the standard Philips
MIX sequence was used. This sequence is an inversion
recovery (IR) sequence interleaved with a spin echo (SE)
sequence. A 180°–90° pulse pair, separated by the
inversion delay TI of 100 ms, is followed by a 90° SE
excitation pulse after the SE repetition time TRSE of
650 ms. These three pulses are continuously repeated after
the IR repetition time TRIR of 1,500 ms. After every 90°
excitation pulse, 20 180° refocusing pulses generate 20
spin echoes (TE 7 ms). The echo trains determine T2, while
the ratios of IR to SE signals determine T1 as described in
[21]. A 3D sequence with five slices was used to minimize
artifacts caused by the otherwise systematically smaller flip
angles at the edges of the 2D slices. Only the central three
slices were used for parameter quantification. T2* was
calculated from the FID of a 2D multi GE sequence using
37 gradient echoes spaced 2.06 ms apart with the first echo
situated at 6 ms, TR 1,000 ms and alpha 90°. T2* was
determined from the FID assuming a mono-exponential
641decay of the signal. To obtain relaxivities, the relaxation
rates (1/Tx)were plotted against the concentration of iron in
the complex using a linear least-square fit.
Cell culture and cell labeling
Mesenchymal stem cell culture was initiated by bone
marrow aspirates from a 20-year-old male patient without
bone marrow disorder who was admitted to our institution
for trauma surgery. The patient gave consent to donating
bone marrow via needle aspiration from the posterior iliac
crest during surgery. The study was approved by the
Institutional Review Board. Preparation of MSCs was done
as described in [22] and cultured using DMEM media
(Invitrogen, Carlsbad, CA) supplemented with 10% FCS
(HyClone, Logan, UT) and 1% penicillin/streptomycin
(Mediatech, Manassas, VA) under standard cell culture
conditions (37°C, 5% CO2). MSCs were plated at 80%
confluency and let to adhere for one day. Labeling was
performed using either 50 μg iron per ml ferucarbotran in
DMEM or 50 μg iron per ml ferucarbotran + 5 μg/ml
protamine in DMEM + 25% FCS. To investigate whether
the addition of FCS might result in efficient uptake,
labeling was also performed with 50 μg iron per ml
ferucarbotran in DMEM + 25% FCS. Flasks were
incubated under standard cell culture conditions for 1, 2,
6, 10 or 24 h. Cells were then washed three times by
sedimentation (25°C, 400 ×g, 5 min) with phosphate
buffered saline (PBS, Invitrogen) and counted in a
Neubauer counting chamber. Trypan blue exclusion testing
was performed. Cell counts of 150,000 were resuspended
in 400 μl Ficoll solution and transferred into 2.0 ml
cylindrical tubes for MR imaging. The isotonic Ficoll
solution was prepared with a density of 1.07 g/ml and
preserved the viability of the labeled cells during imaging
[23].
MR imaging and data analysis
MR images of labeled cells were obtained using a clinical 3-T
MR scanner (Signa EXCITE HD 3 T, GE Medical Systems,
Milwaukee, WI) and a standard circularly polarized quad-
rature knee coil (Clinical MR Solutions, Brookfield, WI). T1-
and T2-weighted spin echo (SE) sequences were obtained
with varying TR (4,000, 1,000, 500, 250 ms) and TE (60, 45,
30, 15 ms). T2*-weighted gradient echo (GE) sequences were
obtained with a flip angle of 30°, a TR of 500 ms and varying
TE(31.2,20.8,15.6,10.4,5.2ms).Imageswereacquiredwith
a field of view (FOV) of 120×120 mm, a matrix of 256×196
pixels,aslicethicknessof1and5 mm andoneacquisition.To
avoid susceptibility artifacts from surrounding air, all probes
were immersed in water at room temperature. MR images
were transferred as DICOM images to a SUN/SPARC
workstation (Sun Microsystems, Mountain View, CA) and
processed by a self-written IDL program (Interactive Data
Language by Research Systems, Boulder, CO). T1 and T2
relaxation times of the cell samples were calculated
assuming monoexponential decay and using a non-linear
function least-square curve fitting on a pixel-by-pixel
basis. T1 relaxation times were calculated using SE
images with a fixed TE of 15 ms. T2 relaxation times
were calculated using SE images with a fixed TR of
4,000 ms and variable TE values of 60, 45, 30 and 15.
T2* relaxation times were calculated using GE images
with a fixed TR of 500 ms and variable TE values of
31.2, 20.8, 15.6, 10.4 and 5.2 ms. The signal intensity for
each pixel as a function of time was expressed as follows:
SIpixel xy (t) = So (pixel xy) [1-exp(-t/T1pixel xy)] for T1 and
SIpixel xy (t) = So (pixel xy) exp(-t/T2pixel xy)f o rT 2a n d
T2*. T1, T2 and T2* relaxation times of cell samples
were derived by ROI measurements on the resultant T1, T2
and T2* maps. Care was taken to analyze only data points
with signal intensities significantly above the noise level.
Relaxation rates (1/Tx) were derived, and the means and
standard deviations of triplicate samples were calculated.
Spectrometry
The iron concentrations of all test samples were determined
by inductively coupled plasma atomic emission spectrom-
etry (ICP-AES) (IRIS Advantage, Thermo Jarrell-Ash,
MA). Samples were dissolved in the microwave (400 W for
55 min) by adding 65% HNO3 and 30% H2O2. The
solutions obtained were nebulized into an argon plasma.
Collaborators from Bayer Schering Pharma AG Berlin who
were blinded with respect to the content of the samples
performed these analyses. Means and standard deviations
of triplicate samples were derived.
Electron microscopy
Cells were treated as described and then fixed with 2.5%
glutaraldehyde-cacodylate buffer overnight for electron
microscopy as described in [24]. In brief, cells were post-
fixed in 1% OsO4 and embedded in Epon resin. Thin
sections were cut and examined with an EM 10 electron
microscope (Carl Zeiss, Oberkochen, Germany). One
investigator (A.M.) evaluated the cells for any structural
changes as a result of the labeling process as well as the
localization of the contrast agent inside the cell.
Results
Contrast agent physicochemical properties
Large, microscopically and macroscopically visible pre-
cipitates were observed when ferucarbotran was mixed
642with protamine in DMEM alone. The quantity and size of
the precipitates grew steadily with time. Stable particle
formation, determined by sequential measurement of
hydrodynamic diameter over a period of 24 h, was
achieved with the addition of 25% of FCS to DMEM.
This was subsequently used as our labeling medium. The
physicochemical properties of ferucarbotran with varying
concentrations of protamine are seen in Fig. 1. With
increasing protamine concentrations, the hydrodynamic
diameter increases, as does the width of the size distribu-
tion, that is, there are larger but also less uniform complex
populations. Surface charge decreases with increasing
concentrations of protamine, with the complex switching
from a negative to positive surface charge between
protamine concentrations of 7 and 10 μg/ml. This was
expected as ferucarbotran is negatively charged, whereas
protamine exhibits a positive charge.
With increasing protamine concentration, and as such,
increasing complex size, the r1 and r2 relaxivities decrease,
whereas the r2
* relaxivity increases (Fig. 2). This is in
accordance with findings with contrast agents of different
sizes [25]. There seems to be a plateau effect with higher
concentrations of protamine; however, because of instable
complex formation seen with concentrations above
10 μg/ml, we were unable to confirm this. We believe
that a concentration of 5 μg/ml is optimal for uptake in
MSCs as this combines a complex size and electrical charge
that are not too large, are still negative and have favorable
relaxivity properties. At a concentration of 5 μg/ml, the
complexes displayed the following relaxivities (in DMEM +
25% FCS, 25°C, 1.5 T): r1 2.50±0.13 s
−1mM
−1,r 2 20.16±
5.04 s
−1mM
−1 and r2
* 574.00±10.64 s
−1mM
−1.
Cell labeling and MR imaging
Simple incubation On qualitative T2-weighted images,
contrast effect was visible after 6 or more h of incubation
with ferucarbotran in DMEM and after 24 h of incubation
with ferucarbotran in DMEM + 25% FCS (Fig. 3).
Quantitatively, R1,R 2 and R2
* relaxation rates gradually
increased with increasing incubation time (Fig. 4). The
effect on relaxation rates was more pronounced with cells
labeled with ferucarbotran in DMEM than with ferucarbo-
tran in DMEM + 25% FCS.
Enhanced uptake Qualitative T2-weighted images show
pronounced contrast effects in cells labeled with ferucar-
botran and protamine at all incubation times investigated
(Fig. 3). Quantitatively, all relaxation rates were markedly
increased compared with MSCs labeled without prota-
mine. MSCs incubated for 2 h and longer showed R2
*
rates higher than the corresponding lowest TE (5.2 ms or
0.19 ms
−1) used for imaging (Fig. 4). One hour of
incubation with protamine resulted in R2 and R2
* rates
comparable with simple incubation over 24 h. R1 relax-
ation rates were highest after 6 h of incubation with lower
R1 rates seen after 10 and 24 h of incubation.
Cell viability was >90% for all cell labeling protocols with
no noteworthy differences found among the different
labeling methods and incubation times.
Spectrometry
ICP-AES quantification of the amount of intracellular iron
correlates with the findings of MR imaging (Fig. 5).
Labeling without protamine resulted in a slow increase in
intracellular iron over time. MSCs incubated with DMEM
and FCS showed worse internalization of contrast agent,
with noticeable changes in intracellular iron content only
after 24 h of incubation. MSCs labeled with protamine
displayed the highest iron uptake at an incubation time of 2
h with a decline in intracellular iron concentrations seen
with 6, 10 and 24 h of incubation. This may possibly be
Fig. 1 Hydrodynamic
diameters and zeta potentials of
ferucarbotran (50 mg iron per
ml) with increasing
concentrations of protamine in
DMEM with 25% FCS. With
increasing concentration of
protamine the complexes
increase in average size and size
distribution. Data points are
z-average and zeta potential
means ± standard deviations of
five and ten measurements,
respectively. Note the zeta
potentials become positive with
a protamine concentration
between 7 and 10 μg/ml
643because of lysosomal digestion of the contrast agent
followed by efflux of contrast agent out of the cell.
Notably, the amount of iron uptake after 1 h with protamine
approaches the intracellular iron content after 24 h of
incubation without protamine.
Electron microscopy
Electron microscopy of MSCs labeled with ferucarbotran
alone and ferucarbotran with protamine showed accumula-
tion of contrast agent/contrast agent complex intracellular-
ly in the cytoplasm only. The contrast agent was not seen
within the nucleus (Fig. 6). The contrast agent is located in
membrane-bound structures indicative of lysosomes, a
finding that is in line with those of previous studies [18].
Discussion
We have shown that the combination of ferucarbotran and
protamine is a fast, efficient and potentially clinically
applicable method for labeling MSCs for MR imaging.
Protamine has been previously used to improve transfec-
tion of oligonucleotides [15], DNA [14] and cellular uptake
of ferumoxides [17]. Being a small protein with a net
positive charge, protamine is complexed to negatively
charged particles by electrostatic interaction [26]. In the
application of DNA transfection, the protein enhances
cellular uptake and inhibits nuclease digestion by conden-
sing DNA [27]. In the application of improving cellular
contrast agent uptake, results obtained with ferumoxides
and protamine show increasing labeling efficiencies with
protamine [17, 28, 29]. To our knowledge, this is the first
time that cell labeling with ferucarbotran and protamine is
reported.
Cell uptake mechanisms for ferucarbotran have not been
studied in detail. Ferumoxide, a slightly larger SPIO with a
neutral charge, is internalized primarily through scavenger
receptor-mediated endocytosis [30]. Scavenger receptors
are known to play a role in LDL uptake in macrophages;
however, they can internalize structurally unrelated sub-
stances such as fibrillar amyloid-β, anionic polysacchar-
ides or bacteria [31]. The cell uptake process involves
clathrin, a protein that forms basket-like scaffolds around
invaginations caused by receptor ligand complexes on the
cell membrane [32, 33]. Although ferumoxides are neutral
and ferucarbotran negatively charged, scavenger receptors
Fig. 2 Relaxivities of com-
plexes of ferucarbotran (50 mg
iron per ml) related to the molar
concentration of iron and
increasing concentrations of
protamine [in labeling media
(DMEM + 25% FCS), 1.5 T,
25°C]
Fig. 3 T2-weighted MR im-
ages (SE, TE 60, TR 4,000, 3 T,
5 mm) of Eppendorf tubes
containing 150,000 MSCs in
400 ml Ficoll. Ferucarbotran
concentration used for labeling
was 50 μg iron per ml, and
protamine concentration was
5 μg/ml
644encompass a number of subtypes with different properties;
thus, this explanation may hold for ferucarbotran as well.
The primary problem we experienced when using prota-
mine in combination with ferucarbotran in standard labeling
solution not supplemented with 25% FCS was the formation
oflarge aggregateswithinminutes.The size of theaggregates
made them visible to the naked eye, and as such rendered
them unsuitable for cell labeling. Similar behavior was
noticed when protamine was used to complex oligonucleo-
tides, and it was found that the addition of albumin hindered
aggregation [34, 35]. When we attempted to add albumin at
different concentrations to a ferucarbotran and protamine
solution, no beneficial effect was noticed. However, the
addition of FCS at different concentrations slowed (10%) or
entirely inhibited (25%) aggregation as demonstrated by
serial measurement of hydrodynamic diameter over the
course of 24 h. We postulate that components of FCS other
than or in addition to albumin coat the ferucarbotran
protamine complexes and prevent aggregation.
The physicochemical properties of the ferucarbotran
protamine complex are interesting, as particles of different
sizes, surface charges and relaxivities can be created by
simply varying the concentration of protamine. The MSCs
we labeled were responsive to labeling with ferucarbotran
Fig. 4 R1,R 2 and R2
* relax-
ation rates of samples of
150,000 MSCs in 400 μl Ficoll
labeled with ferucarbotran (solid
block), ferucarbotran in 25%
FCS (diamond) and ferucarbo-
tran with protamine (solid tri-
angle) at 3 T. The R2
* rate
0.19 ms
−1 corresponds to the
lowest measurable TE time of
5.2 ms. Data points are mean
relaxation rates of triplicate
samples ± standard deviation
645and protamine at a concentration at 5 μg/ml. However,
other cell lines may not be and may be more responsive to a
larger or smaller particle size. While we found it difficult to
create stable ferucarbotran protamine complexes with a
larger hydrodynamic diameter than approximately 1,100 nm
(corresponding to a protamine concentration of 10 μg/ml),
the spectrum of hydrodynamic diameters from approxi-
mately 100 to 1,100 nm was easily controlled with different
protamine concentrations. This may prove beneficial for cell
labeling.
Protamine has been used clinically for over 30 years as
an antidote for heparin anticoagulation and for slow-release
formulations of insulin. One well-known complication is
allergoid reactions up to anaphylactic shock [36]. The
incidence is fairly low for patients using NPH insulin
(0.13%) [37], but might increase with preconditioning to
protamine, such as in a patient undergoing cardiovascular
surgery after years of NPH insulin use [36]. If this becomes
a problem for our application, low molecular weight
protamine fragments — protamine that is enzymatically
digested into smaller proteins — may be a solution, as
these fragments seem to display lower immunogenicity
while retaining most of the beneficial properties of
protamine [38]. However, given protamine’s long safety
record and seeing that concerns of anaphylaxis may not
even be applicable in our setting as protamine is located
inside the cell and is invisible to the patient’s immune
system, we believe protamine is safe for use in enhancing
contrast agent uptake.
Cell labeling can be achieved through a number of
means. Cells can be labeled using simple incubation with
contrast agent alone, an uptake-enhancing agent can be
Fig. 5 Intracellular contrast
agent content in pg iron per cell
as determined by ICP-AES.
Data points are mean values of
triplicate samples ± standard
deviation
Fig. 6 Transmission electron microscopy of MSCs: (a) unlabeled control, (b) labeled with ferucarbotran for 24 h, (c) labeled with
ferucarbotran and protamine for 2 h. Magnification is approximately 1:8,000
646added, or other means such as electroporation can be
utilized. Simple incubation has been used extensively for
cell labeling with adequate results for some cell types [18].
In our case, after 24 h of incubation, we noticed contrast
agent uptake that resulted in detection on qualitative
imaging; however, even better results were obtained with
much lower incubation times when protamine was added.
Other transfection agents such as lipofectin or poly-L-
lysine (PLL) can be used to expedite labeling with great
success [39, 40]. However, unlike protamine, most uptake-
enhancing agents are not approved by health authorities
and as such will have limited usefulness for cell tracking
applications in humans. Other techniques such as electro-
poration circumvent this problem by avoiding uptake-
enhancing agents altogether [41, 42]. This method can
offer almost instant labeling, but results in significantly
lower cell viability after the labeling process. A method
utilizing protamine with near-instant labeling but without
deleterious effects on viability is preferred.
We acknowledge various limitations of our study. In
particular, although such a technique is promising for
in vivo cell tracking purposes, results must be validated in
further preclinical testing. We realize that our enhanced
labeling method relies on fetal calf serum (FCS) in order to
stabilize the complexes and to culture the MSCs. FCS is
not approved for human use, and as such, the tolerance and
clinical applicability are unknown. Also, potential detri-
mental effects on long-term cell survival or differentiation
capacity should be assessed.
In conclusion, we have shown that the addition of
protamine greatly improves cellular labeling of MSCs with
ferucarbotran. Given the high sensitivity of iron oxide-
based contrast agents and the straightforward labeling
method with the health authority-approved protamine,
future use of this technique to label stem cells destined for
cellular and molecular imaging is promising.
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